Engineering an indoleamine 2,3-dioxygenase immunotherapy via selective cysteine-to-serine mutations is a research paper published in Molecular Systems Design & Engineering (2025). On theSindex it has a DataRank of 0.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: R01 AI133623
National Institutes of Health
Grant: R01 DE027301
National Institutes of Health
Grant: R01 DK091658
National Institutes of Health
Grant: R01 DK098589
National Institutes of Health
Grant: R03 EB019684
National Institutes of Health
Grant: R35 GM133697
National Science Foundation
Grant: DMR-1455201
NIDDK NIH HHS
Grant: R01 DK129690
NIAID NIH HHS
Grant: R01 AI171045